LIVN Stock Overview
About the company
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Rewards
Risk analysis
No risks detected for LIVN from our risk checks.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LivaNova PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.02 |
| 52 Week High | US$88.00 |
| 52 Week Low | US$40.26 |
| Beta | 0.87 |
| 1 Month Change | -12.44% |
| 3 Month Change | -24.53% |
| 1 Year Change | -48.44% |
| 3 Year Change | 5.39% |
| 5 Year Change | -51.33% |
| Change since IPO | 250.17% |
Recent News & Updates
What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?
Mar 13
Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Feb 15Recent updates
What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?
Mar 13Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Feb 15Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
Nov 25Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Oct 29LivaNova Loses Profit Momentum On Higher R&D Expense
Oct 13LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 11FDA labels recall of blood bypass pump systems by LivaNova as most serious
Sep 30Returns On Capital At LivaNova (NASDAQ:LIVN) Have Hit The Brakes
Aug 09LivaNova PLC Non-GAAP EPS of $0.53 beats by $0.01, revenue of $254.2M beats by $4.65M, lowers FY earning guidance
Aug 03Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Jul 19A Look At The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Jun 27LivaNova Matures Into Profitability, Still Waiting On DTD
May 10Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Apr 05LivaNova Continues To Be A Spring-Loaded Opportunity In Neuromodulation
Feb 11Is LivaNova PLC (NASDAQ:LIVN) Trading At A 35% Discount?
Jan 30At US$87.75, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?
Dec 29Does LivaNova (NASDAQ:LIVN) Have A Healthy Balance Sheet?
Nov 29Milan Court Decision Does Not Change LivaNova Bullish Story
Nov 16LivaNova's Peculiar Situation Makes For A Cheap Option
Aug 23At US$76.94, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
Aug 14LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Above Their Intrinsic Value Estimate
Jul 16LivaNova gets FDA nod for aura6000 system obstructive sleep apnea study
Jun 15LivaNova PLC's (NASDAQ:LIVN) CEO Might Not Expect Shareholders To Be So Generous This Year
Jun 03Here's Why LivaNova (NASDAQ:LIVN) Can Afford Some Debt
May 04Living La LivaNova Once More: Shakeup Pays In Capital Gains
May 03LivaNova PLC 2021 Q1 - Results - Earnings Call Presentation
Apr 30LivaNova and Alphabet's Verily enroll first patient in difficult-to-treat depression study
Apr 26LivaNova PLC (NASDAQ:LIVN): Is Breakeven Near?
Mar 30Does LivaNova's (NASDAQ:LIVN) Share Price Gain of 27% Match Its Business Performance?
Feb 23Would LivaNova (NASDAQ:LIVN) Be Better Off With Less Debt?
Jan 28LivaNova PLC's (NASDAQ:LIVN) Intrinsic Value Is Potentially 51% Above Its Share Price
Dec 24
Living La LivaNova: 50% Upside Potential Is Under-Reflected In Current Pricing
Dec 12Shareholder Returns
| LIVN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.3% | 1.0% | 0.9% |
| 1Y | -48.4% | -17.2% | -16.0% |
Return vs Industry: LIVN underperformed the US Medical Equipment industry which returned -15.4% over the past year.
Return vs Market: LIVN underperformed the US Market which returned -15.5% over the past year.
Price Volatility
| LIVN volatility | |
|---|---|
| LIVN Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LIVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: LIVN's weekly volatility (5%) has been stable over the past year.
LivaNova PLC Fundamentals Summary
| LIVN fundamental statistics | |
|---|---|
| Market Cap | US$2.25b |
| Earnings (TTM) | -US$86.25m |
| Revenue (TTM) | US$1.02b |
2.2x
P/S Ratio-26.1x
P/E RatioIs LIVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIVN income statement (TTM) | |
|---|---|
| Revenue | US$1.02b |
| Cost of Revenue | US$325.08m |
| Gross Profit | US$696.73m |
| Other Expenses | US$782.97m |
| Earnings | -US$86.25m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 03, 2023
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 68.19% |
| Net Profit Margin | -8.44% |
| Debt/Equity Ratio | 44.8% |
How did LIVN perform over the long term?
See historical performance and comparison